The triple-negative breast cancer (TNBC) subgroup, which is estrogen-receptor (ER) negative, progesterone-receptor (PR) negative, and HER-2 negative, accounts for approximately 15–18% of breast cancers [1, 2]. This evidence concerns the gene ESR1 and breast carcinoma.